ChartMill assigns a Buy % Consensus number of 82% to RVPH. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-12-23 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-12-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-11-19 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-10-28 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-10-27 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-09-29 | Chardan Capital | Initiate | Buy |
| 2025-09-19 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-09-15 | Benchmark | Maintains | Speculative Buy -> Speculative Buy |
| 2025-08-18 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-08-18 | Roth Capital | Reiterate | Buy -> Buy |
| 2025-08-15 | Maxim Group | Maintains | Buy -> Buy |
| 2025-06-27 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-06-03 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-05-20 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-04-24 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-04-01 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-01-22 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-01-21 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-01-10 | Roth MKM | Initiate | Buy |
| 2025-01-10 | Maxim Group | Upgrade | Hold -> Buy |
| 2024-11-14 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-11-13 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-09-23 | EF Hutton | Initiate | Buy |
| 2024-08-26 | Benchmark | Reiterate | Speculative Buy -> Speculative Buy |
| 2024-08-16 | Maxim Group | Downgrade | Buy -> Hold |
| 2024-07-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-05-28 | Benchmark | Reiterate | Speculative Buy -> Speculative Buy |
| 2024-04-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
13 analysts have analysed RVPH and the average price target is 5.87 USD. This implies a price increase of 2018.86% is expected in the next year compared to the current price of 0.2768.
The consensus rating for REVIVA PHARMACEUTICALS HOLDI (RVPH) is 81.5385 / 100 . This indicates that analysts generally have a positive outlook on the stock.